Advertisement
U.S. markets open in 6 hours 41 minutes

Kancera AB (publ) (KAN.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
1.0980+0.0340 (+3.20%)
At close: 05:15PM CET

Kancera AB (publ)

Karolinska Institutet Science Park
Nanna Svarts väg 4
Solna 171 65
Sweden
46 8 50 12 60 80
https://www.kancera.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 5

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter SelinChief Executive Officer2.62MN/A1973
Dr. Thomas Olin Ph.D.Executive VP & Director3.45MN/A1958
Mr. Hans RichterChief Financial OfficerN/AN/A1949
Dr. Robert EdforsChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.

Corporate Governance

Kancera AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.